MaaT Pharma Statistics
Want to see FR:MAAT full AI Analyst Report?
MaaT Pharma (MAAT) Stock Statistics & Valuation Metrics
Total Valuation
MaaT Pharma has a market cap or net worth of EUR 19.38M. The enterprise value is EUR 51.54M.
- Market Cap
- EUR 19.38M
- Enterprise Value
- EUR 51.54M
Share Statistics
MaaT Pharma has 18,856,394 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 18,856,394
- Owned by Insiders
- ―
- Owned by Institutions
- 0.50%
Financial Efficiency
MaaT Pharma’s return on equity (ROE) is -17.27 and return on invested capital (ROIC) is -101.22%.
- Return on Equity (ROE)
- -17.27
- Return on Assets (ROA)
- -0.70
- Return on Invested Capital (ROIC)
- -101.22%
- Return on Capital Employed (ROCE)
- -1.24
- Revenue Per Employee
- 75.40K
- Profits Per Employee
- -517.68K
- Employee Count
- 60
- Asset Turnover
- 0.10
- Inventory Turnover
- 37.32
Valuation Ratios
The current PE Ratio of MaaT Pharma is -0.54. MaaT Pharma’s PEG ratio is -0.05.
- PE Ratio
- -0.54
- PS Ratio
- 6.09
- PB Ratio
- -1.19
- Price to FCF
- -1.20
- Price to Operating Cash Flow
- -1.23
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, MaaT Pharma had revenue of 4.52M and earned -31.06M in profits. Earnings per share was -1.95.
- Revenue
- 4.52M
- Gross Profit
- 1.39M
- Operating Income
- -34.15M
- Pretax Income
- -34.85M
- Net Income
- -31.06M
- EBITDA
- -32.41M
- Earnings Per Share (EPS)
- -1.95
Cash Flow
In the last 12 months, operating cash flow was -15.71M and capital expenditures -454,000, giving a free cash flow of -16.16M billion.
- Operating Cash Flow
- -15.71M
- Free Cash Flow
- -16.16M
- Free Cash Flow per Share
- -0.86
Dividends & Yields
MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -83.53%
- Earnings Yield
- -176.98%
Stock Price Statistics
- Beta
- 0.11
- 52-Week Price Change
- -73.09%
- 50-Day Moving Average
- 1.30
- 200-Day Moving Average
- 3.81
- Relative Strength Index (RSI)
- 40.15
- Average Volume (3m)
- 103.40K
Important Dates
MaaT Pharma upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 29, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
MaaT Pharma as a current ratio of 1.94, with Debt / Equity ratio of 969.43%
- Current Ratio
- 1.94
- Quick Ratio
- 1.94
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- 0.23
- Interest Coverage Ratio
- -26.91
Taxes
In the past 12 months, MaaT Pharma has paid -3.79M in taxes.
- Income Tax
- -3.79M
- Effective Tax Rate
- 0.11
Enterprise Valuation
MaaT Pharma EV to EBITDA ratio is -0.78, with an EV/FCF ratio of -1.61.
- EV to Sales
- 8.19
- EV to EBITDA
- -0.78
- EV to Free Cash Flow
- -1.61
- EV to Operating Cash Flow
- -1.66
Balance Sheet
MaaT Pharma has EUR 17.10M in cash and marketable securities with EUR 23.78M in debt, giving a net cash position of -EUR 6.67M billion.
- Cash & Marketable Securities
- EUR 17.10M
- Total Debt
- EUR 23.78M
- Net Cash
- -EUR 6.67M
- Net Cash Per Share
- -EUR 0.35
- Tangible Book Value Per Share
- -EUR 0.91
Margins
Gross margin is 50.19%, with operating margin of -1195.06%, and net profit margin of -1080.20%.
- Gross Margin
- 50.19%
- Operating Margin
- -1195.06%
- Pretax Margin
- -1127.33%
- Net Profit Margin
- -1080.20%
- EBITDA Margin
- -1045.34%
- EBIT Margin
- -1195.06%
Analyst Forecast
The average price target for MaaT Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -19.02%
- EPS Growth Forecast
- 10.39%
Scores
- Smart Score
- ―
- AI Score
- 45

